Year: 2023
Type: review
Abstract: ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review astaxanthin which has plausible mechanisms for slowing ALS progression including antioxidant, anti-inflammatory, and anti-apoptotic effects. While there are no ALS-specific pre-clinical studies, one verified "ALS reversal" occurred in a person using a combination of alternative therapies which included astaxanthin. There have been no trials of astaxanthin in people living with ALS. Natural astaxanthin appears to be safe and inexpensive. Based on the above information, we support further pre-clinical and/or clinical trials of astaxanthin in disease models and PALS, respectively, to further elucidate efficacy.
Authors: Timothy Fullam, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Morgan Beauchamp, Michael Benatar, Tulio Bertorini, Robert Bowser, Mark Bromberg, Javier Mascias Cadavid, Gregory T. Carter, Mazen Dimachkie, Dave Ennist, Eva L. Feldman, Terry Heiman-patterson, Sartaj Jhooty, Isaac Lund, Christopher Mcdermott, Gary Pattee, Dylan Ratner, Paul Wicks, Richard Bedlack
Institutions: The University of Texas at San Antonio, Loma Linda University, Medical College of Wisconsin, Augusta University, University of North Carolina at Chapel Hill, University of Miami, University of Tennessee Health Science Center, Barrow Neurological Institute, University of Utah, Washington State University Spokane, University of Kansas, FHWien der WKW, University of Michigan, Temple University Hospital, University of Sheffield, University of Nebraska Medical Center, Tulane University, Duke University
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4317888293